How to buy AbbVie (ABBV) shares in Australia
Learn how to easily invest in AbbVie shares.
AbbVie Inc (ABBV) is a leading drug manufacturers - general business with stocks listed in the US. It opened the day at US$144.79 after a previous close of US$144.57. During the day the price has varied from a low of USD144.73 to a high of USD146.08. The latest price was USD145.51 (25 minute delay). AbbVie is listed on the NYSE. All prices are listed in US Dollars.
How to buy shares in AbbVie
- Compare share trading platforms. To buy shares in a company listed in the US from Australia you'll need to find a trading platform that offers access to US stock markets. Look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, which will typically include your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for AbbVie. Find the share by name or ticker symbol: ABBV. Research its history to confirm it's a solid investment that matches your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until AbbVie reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying using consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$144.57, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of AbbVie, depending on your broker.
- Check in on your investment. Congratulations, you own a part of AbbVie. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights.
What's in this guide?
AbbVie stock price (NYSE:ABBV)Use our graph to track the performance of ABBV stocks over time.
AbbVie shares at a glance
|52-week range||US$128.2406 - US$162.7487|
|50-day moving average||US$144.3008|
|200-day moving average||US$147.0854|
|Dividend yield||US$5.92 (4.32%)|
|Earnings per share (TTM)||US$3.66|
AbbVie price performance over time
|1 week (2023-11-29)||5.06%|
|1 month (2023-11-06)||3.05%|
|3 months (2023-09-06)||-0.07%|
|6 months (2023-06-06)||7.44%|
|1 year (2022-12-06)||-11.12%|
|2 years (2021-12-06)||19.91%|
|3 years (2020-12-04)||35.64%|
|5 years (2018-12-06)||61.09%|
Compare trading platforms to buy AbbVie shares
Is it a good time to buy AbbVie stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Is AbbVie under- or over-valued?
Valuing AbbVie stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AbbVie's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
AbbVie's P/E ratio
AbbVie's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 40x. In other words, AbbVie shares trade at around 40x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
AbbVie's PEG ratio
AbbVie's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.2788. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AbbVie's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
AbbVie's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$28 billion (£22.2 billion).
The EBITDA is a measure of a AbbVie's overall financial performance and is widely used to measure stock profitability.
AbbVie share price volatility
Over the last 12 months, AbbVie's shares have ranged in value from as little as US$128.2406 up to US$162.7487. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while AbbVie's is 0.449. This would suggest that AbbVie's shares are less volatile than average (for this exchange).
|Revenue TTM||US$55.1 billion|
|Operating margin TTM||17.76%|
|Gross profit TTM||US$41.5 billion|
|Return on assets TTM||8.65%|
|Return on equity TTM||46.32%|
|Market capitalisation||US$256.5 billion|
TTM: trailing 12 months
AbbVie share dividends
Dividend payout ratio: 49.66% of net profits
Recently AbbVie has paid out, on average, around 49.66% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.32% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), AbbVie shareholders could enjoy a 4.32% return on their shares, in the form of dividend payments. In AbbVie's case, that would currently equate to about $5.92 per share.
While AbbVie's payout ratio might seem fairly standard, it's worth remembering that AbbVie may be investing much of the rest of its net profits in future growth.
AbbVie's most recent dividend payout was on 15 February 2024. The latest dividend was paid out to all shareholders who bought their shares by 12 January 2024 (the "ex-dividend date").
AbbVie's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like AbbVie.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
AbbVie's total ESG risk score
Total ESG risk: 34.86
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and AbbVie's overall score of 34.86 (as at 01/01/2019) is pretty weak – landing it in it in the 66th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like AbbVie is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
AbbVie's environmental score
Environmental score: 4.96/100
AbbVie's environmental score of 4.96 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that AbbVie is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
AbbVie's social score
Social score: 22.65/100
AbbVie's social score of 22.65 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that AbbVie is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
AbbVie's governance score
Governance score: 16.25/100
AbbVie's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that AbbVie is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
AbbVie's controversy score
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. AbbVie scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that AbbVie hasn't always managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||34.86|
|Total ESG percentile||65.78|
|Environmental score percentile||7|
|Social score percentile||7|
|Governance score percentile||7|
|Level of controversy||3|
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; and California Institute for Biomedical Research (Calibr). The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Stocks similar to AbbVie
Frequently asked questions
More guides on Finder
Shein IPO: How to invest in the Shein IPO
What you need to know about investing in Shein from Australia.
Best performing stocks on the ASX in 2023 (Updated weekly)
Looking for the best performing stocks in Australia? We update this list weekly.
Tiger Brokers review for Australians
If you're thinking of trading stocks with Tiger Brokers, check out our review of this online broker's fees, safety and pros and cons first.
How to buy Gol Linhas Aereas Inteligentes SA ADR (GOL) shares in Australia
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
How to buy Caltex Australia shares
Steps to owning and managing Caltex Australia shares from .
A beginner’s guide to Lego investing
Looking for alternative investments? With a ROI of up to 3,593% lego may be worth considering. Read on to find out which lego sets are worth the investment.
The cheapest stock brokers in Australia (Dec 2023)
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.
What is the money market?
Learn about the money market and everyday consumer money market products.
Is investing in crowdfunding a safe investment?
Equity crowdfunding offers a unique opportunity for investors and for Australian startups, but Australia’s regulatory framework surrounding crowdfunding still lags behind the rest of the world.
The best trading platforms in Australia for 2023
Follow these tips to find the best share trading platform for you.
Ask an Expert